Dr. Braghiroli on Individualization of Treatment in CRC

Maria Ignez Braghiroli, MD
Published: Wednesday, Oct 12, 2016



Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer (CRC) depending on the mutations they may harbor.

For example, explains Braghiroli, patients with RAS-mutated CRC do not seem to respond positively to anti-EGFR medications. Moreover, patients with BRAF-mutated disease generally tend to have a worse prognosis.

Multiple studies have focused on the respective efficacies of BRAF and MEK inhibitors, MEK inhibitors, as well as combinations of these agents. Overall, says Braghiroli, these various subgroups of patients will require individualized treatment approaches.


Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer (CRC) depending on the mutations they may harbor.

For example, explains Braghiroli, patients with RAS-mutated CRC do not seem to respond positively to anti-EGFR medications. Moreover, patients with BRAF-mutated disease generally tend to have a worse prognosis.

Multiple studies have focused on the respective efficacies of BRAF and MEK inhibitors, MEK inhibitors, as well as combinations of these agents. Overall, says Braghiroli, these various subgroups of patients will require individualized treatment approaches.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x